Dr. Thomas E. Hutson, DO,PHARMD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio University, College of Osteopathic Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 265
Licensed in Texas since 2003, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Ohio University, College of Osteopathic Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license L5774 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Medical Center Lubbock, TX
- Hendrick Medical Center Abilene, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
- Texas Tech University Health Sciences Center Lubbock (359 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 265
- Services billed
- 27,852
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 16,600 | 47 |
| Injection, fosaprepitant, 1 mg | 12,900 | 51 |
| Injection, paclitaxel, 1 mg | 9,054 | 26 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,258 | 43 |
| Injection, denosumab, 1 mg | 2,220 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,066 | 108 |
| Injection, palonosetron hcl, 25 mcg | 1,140 | 67 |
| Injection, granisetron hydrochloride, 100 mcg | 800 | 44 |
| Blood test, comprehensive group of blood chemicals | 714 | 164 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 691 | 163 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Dallas, TX | 78 |
| Xtandi (enzalutamide) | 71 |
| Abiraterone Acetate | 56 |
| Levothyroxine Sodium Other prescribers in Dallas, TX | 42 |
| Inlyta (axitinib) | 29 |
| Nubeqa (darolutamide) | 24 |
| Orgovyx (relugolix) | 21 |
| Tramadol Hcl Other prescribers in Dallas, TX | 19 |
| Lenvima (lenvatinib mesylate) | 19 |
| Gabapentin Other prescribers in Dallas, TX | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 21 payments worth $28,159 in total to this clinician.
| Aveo Pharmaceuticals, Inc. | $16,443 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $6,908 |
| Merck Sharp & Dohme LLC | $4,480 |
| Exelixis Inc. | $153 |
| Janssen Biotech, Inc. | $100 |
| Eisai Inc. | $37.42 |
| AbbVie Inc. | $36.73 |
| Compensation for services other than consulting (speaking, faculty) | $26,140 |
|---|---|
| Travel and Lodging | $1,579 |
| Food and Beverage | $440 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $6,660 |
| Aveo Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $6,660 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| AstraZeneca Pharmaceuticals LP Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| AstraZeneca Pharmaceuticals LP Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
| Aveo Pharmaceuticals, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $1,110 |
| Aveo Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Frisco, TX · in-kind | $588 |
| Aveo Pharmaceuticals, Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $370 |
| Aveo Pharmaceuticals, Inc. Oct 25, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Denver, CO · in-kind Company’s descriptionAirfare | $358 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $6,660 |
| Aveo Pharmaceuticals, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology Company’s descriptionSpeaker Compensation | $1,110 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $300 |
| Aveo Pharmaceuticals, Inc. Oct 25, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Denver, CO · in-kind Company’s descriptionAirfare | $358 |
| Aveo Pharmaceuticals, Inc. Oct 25, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Denver, CO · in-kind Company’s descriptionHotel | $323 |
| AstraZeneca Pharmaceuticals LP Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $1,640 |
| AstraZeneca Pharmaceuticals LP Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) LYNPARZA · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| Aveo Pharmaceuticals, Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $370 |
| Aveo Pharmaceuticals, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) FOTIVDA · Oncology | $6,660 |
| Merck Sharp & Dohme LLC Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Aveo Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Frisco, TX · in-kind | $588 |
| Aveo Pharmaceuticals, Inc. Apr 4, 2025 | Travel and Lodging FOTIVDA · Oncology · travel to Frisco, TX · in-kind | $310 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $23,465 in research payments for these studies, mostly to the institutions running them.
- A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca UK Limited - BLU667 1101 ARROW ongoing
Hoffmann-la Roche Limited - PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Re…
Novartis Pharmaceuticals Corporation - Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.